Clinical trial · Interventional
Efficacy of Topical Glucosamine Versus Corticosteroid in Oral Lichen Planus
Efficacy of Topical Glucosamine Versus Corticosteroid on Tumor Necrosis Factor -Alpha Induced Apoptosis in Oral Lichen Planus: A Randomized Controlled Clinical Trial With Immunohistochemical Analysis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan. It is classified as a nutraceutical and it is used mainly orally for the therapy of osteoarthritis since GlcN has immunoregulatory capacity and anti-inflammatory effects. Given the Oral lichen planus (OLP) T-cell-mediated pathogenesis; this drug seems to be a promising therapeutic option. The investigators compared the clinical efficacy of topical glucosamine to topical corticosteroid in the treatment of symptomatic OLP and investigated the effect of these two treatment modalities on the expression of tumor necrosis factor-alpha (TNF-α) in oral lichen planus lesions
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oral Lichen Planus | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Glucosamine Hydrochloride | Drug | — | UNRESOLVED |
| Triamcinolone Acetonide | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Glucosamine
- description
- (Topical glucosamine hydrochloride 1%) Four times per day for 8 weeks
- interventionNames
- Drug: Glucosamine Hydrochloride
- type
- ACTIVE_COMPARATOR
- label
- Corticosteroids
- description
- Topical steroid (triamcinolone acetonide 0.1 %) four times per day for 8 weeks
- interventionNames
- Drug: Triamcinolone Acetonide
Primary outcomes (1)
- measure
- Clinical score (CS)
- timeFrame
- Change from Baseline at 12 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 25 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Clinically proven painful bullous/erosive or atrophic forms of OLP * Histopathologically proven bullous/erosive or atrophic forms of OLP Exclusion Criteria: * Lichenoid lesions. * Presence of systemic conditions * Smoking. * Hypersensitivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation as mentioned in medical history. * Pregnancy or breast-feeding. * Presence of skin lesions. * History of previous treatments potentially effective on OLP. * Loss of pliability or flexibility in the tissues involved by the oral lesions of lichen planus. * Histological signs of epithelial dysplasia or lichenoid lesions within the biopsied sites. * Refusing to participate in the study. * Vulnerable groups
References
Publications (0)
Data not yet available